Startup | October 03, 2023
SigTuple’s AI100 with Shonit receives USFDA 510(k) clearance
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
The peptide-based vaccine induces a t cell-dependent response
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
On track to complete the BLA submission in the first half of 2022
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Subscribe To Our Newsletter & Stay Updated
